Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116746 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
A Phase 2 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 8
- Study locations
NCT07116746: Recruiting Phase 2 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
NCT07116746 is a Phase 2 study of Gout and Hyperuricemia that is actively recruiting participants, run by Arthrosi Therapeutics. The registered enrollment target is 25 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116746, a Phase 2 study of Gout and Hyperuricemia, is actively recruiting participants, sponsored by Arthrosi Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Primary Outcome
Proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL at month 6
Conditions Studied
Interventions
- DRUG AR882 75 mg
- DRUG XOI Low Dose
- DRUG XOI High Dose
Study Locations (8)
Florida
- Arthrosi Investigative Site (105) - Margate
- Arthrosi Investigative Site (102) - Miami
- Arthrosi Investigative Site (109) - Tampa
Mississippi
- Arthrosi Investigative Site (106) - Jackson
North Carolina
- Arthrosi Investigative Site (108) - Charlotte
Pennsylvania
- Arthrosi Investigative Site (103) - Duncansville
Texas
- Arthrosi Investigative Site (104) - West Lake Hills
Washington
- Arthrosi Investigative Site (107) - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07116746 shows while recruiting
NCT07116746 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower).
The record links to 7 conditions, with Gout appearing as the primary indexed condition, and to 3 interventions - of which AR882 75 mg is the first listed.
NCT07116746 lists 8 locations in 6 states (Florida, Mississippi, North Carolina).
Frequently Asked Questions
What is clinical trial NCT07116746 about?
NCT07116746 is a clinical study titled "Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients". This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibo...
What is the current status of trial NCT07116746?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-12-03. Estimated completion is 2027-01.
What conditions does trial NCT07116746 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia, Gout Chronic, Uncontrolled Gout, Gouty Arthritis.
What interventions are being tested in trial NCT07116746?
The interventions under investigation include: AR882 75 mg (DRUG), XOI Low Dose (DRUG), XOI High Dose (DRUG).
Who is sponsoring clinical trial NCT07116746?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116746 being conducted?
This trial has 8 study locations across Florida, Mississippi, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07116746's enrollment target sits among peer trials
25 25th of 34 higher than 10 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
RECRUITING · Phase 2
-
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
ACTIVE NOT RECRUITING · Phase 2
-
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
ACTIVE NOT RECRUITING · Phase 2
-
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
COMPLETED · Phase 2
-
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI